Publique un comentario 
Asociación entre el sÃndrome metabólico y los niveles de transaminasas
Resumen
Objetivo: Estimar la prevalencia de transaminasas elevadas (alanina aminotransaminasa y aspartato aminotransaminasa) y determinar su asociación con sÃndrome metabólico.
Métodos: Estudio transversal con procedimientos analÃticos. Análisis secundario de los datos generados por el registro electrónico en salud de un policlÃnico ocupacional. La variable principal fue el diagnóstico del sÃndrome metabólico. Para definir aspartato aminotransaminasa elevada se consideraron valores > 30 U/L en mujeres y valores > 36 U/L en hombres. Para alanina aminotransaminasa, se consideraron valores > 30 U/L en mujeres y valores > 40 U/L en hombres.
Resultados: La prevalencia de sÃndrome metabólico fue de 21,82 %, de aspartato aminotransaminasa elevada fue del 10,30 % y alanina aminotransaminasa elevada del 16,67 %. En la regresión múltiple, se ajustó por las covariables confusoras sexo, edad, ocupación, Ãndice de masa corporal, fumar, alcohol y actividad fÃsica. Se observó que los pacientes con aspartato aminotransaminasa elevada tenÃan 128 % mayor frecuencia de sÃndrome metabólico, respecto a quienes no presentaban valores elevados (razón prevalencia= 2,28; IC95 %: 1,64 - 3,17; p< 0,001). Se encontró que los pacientes con alanina aminotransaminasa elevada tenÃan 148 % mayor frecuencia de presentar sÃndrome metabólico respecto a quienes no presentaban valores elevados (razón prevalencia= 2,48; IC95 %: 1,77 - 3,47; p< 0,001).
Conclusiones: Existe asociación entre las transaminasas hepáticas elevadas y la presencia de sÃndrome metabólico.
Palabras clave
Referencias
Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome - What is it and how should it be managed? Eur J Prev Cardiol. 2019; 26(suppl 2):33-46. DOI: 10.1177/2047487319886404
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12. DOI: 10.1007/s11906-018-0812-z
Li R, Li W, Lun Z, Zhang H, Sun Z, Kanu JS, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC Public Health. 2016; 16:296. DOI: 10.1186/s12889-016-2870-y
Hirode G, Wong RJ. Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA. 2020; 323(24):2526-8. DOI: 10.1001/jama.2020.4501
Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D, Fernández Ballart JD, Salas Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr. 2011; 14(10):1702-13. DOI: 10.1017/S1368980010003320
Tapia JC, Ruiz EF, Ponce OJ, Malaga G, Miranda J. Weaknesses in the reporting of cross-sectional studies according to the STROBE statement the case of metabolic syndrome in adults from Peru. Colombia Médica. 2015; 46(4):168-75. DOI: 10.2510/colomb
Arbañil-Huamán HC. SÃndrome metabólico: Definición y prevalencia. Revista Peruana de GinecologÃa y Obstetricia. 2011 [acceso: 16/09/2021]; 57(4):233-6. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2304-51322011000400004
Adams KJ, Chirinos JL. Prevalencia de factores de riesgo para sÃndrome metabólico y sus componentes en usuarios de comedores populares en un distrito de Lima, Perú. Revista Peruana de Medicina Experimental y Salud Pública. 2018; 35(1):39-45. DOI: 10.17843/rpmesp.2018.351.3598
Wang L, Du Z-H, Qiao J-M, Gao S. Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies. Aging (Albany NY). 2020; 12(10):9825-39. DOI: 10.18632/aging.103247
Zhang J, Wu H, Wang R. Metabolic syndrome and esophageal cancer risk: a systematic review and meta‑analysis. Diabetol Metab Syndr. 2021; 13(1):8. DOI: 10.1186/s13098-021-00627-6
Mariani M, Sassano M, Boccia S. Metabolic syndrome and gastric cancer risk: a systematic review and meta-analysis. Eur J Cancer Prev. 2021; 30(3):239-50. DOI: 10.1097/CEJ.0000000000000618
Myers J, Kokkinos P, Nyelin E. Physical Activity, Cardiorespiratory Fitness, and the Metabolic Syndrome. Nutrients. 2019; 11(7):E1652. DOI: 10.3390/nu11071652
Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome? Curr Vasc Pharmacol. 2018; 16(3):219-27. DOI: 10.2174/1570161115666170621075619
Wang J, Wang Y, Chen F, Ma G, Wang D. Measurement of the Combined Levels of Serum Uric Acid and Alanine Aminotransferase and the Risk of Metabolic Syndrome in a Population Aged 60 Years or More in Northeastern China. Med Sci Monit. 2020; 26:e916459. DOI: 10.12659/MSM.916459
Kunutsor SK, Apekey TA, Walley J. Liver aminotransferases and risk of incident type 2 diabetes: a systematic review and meta-analysis. Am J Epidemiol. 2013; 178(2):159-71. DOI: 10.1093/aje/kws469
Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis. 2014; 236(1):7-17. DOI: 10.1016/j.atherosclerosis.2014.06.006
Chen Y-F, Lin Y-A, Yeh W-C, Tsao Y-C, Li W-C, Fang W-C, et al. The Association between Metabolic Syndrome and Elevated Alanine Aminotransferase Levels in an Indigenous Population in Northern Taiwan: A Community-Based and Cross-Sectional Study. Evid Based Complement Alternat Med. 2020; 2020:6612447. DOI: 10.1155/2020/6612447
Chen K-W, Meng F-C, Shih Y-L, Su F-Y, Lin Y-P, Lin F, et al. Sex-Specific Association between Metabolic Abnormalities and Elevated Alanine Aminotransferase Levels in a Military Cohort: The CHIEF Study. Int J Environ Res Public Health. 2018; 15(3):E545. DOI: 10.3390/ijerph15030545
Zhang J, Wang Z-Y, Zhang J-P, Zhou H, Ding Z. Prevalence of Elevated Alanine Aminotransferase by Diagnostic Criterion, Age, and Gender among Adolescents. Gastroenterol Res Pract. 2020; 2020:4240380. DOI: 10.1155/2020/4240380
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486v
Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, et al. Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Metab Syndr. 2010; 2:65. DOI: 10.1186/1758-5996-2-65
Yamamoto JM, Prado-Núñez S, Guarnizo-Poma M, Lazaro-Alcantara H, Paico-Palacios S, Pantoja-Torres B, et al. Association between serum transaminase levels and insulin resistance in euthyroid and non-diabetic adults. Diabetes Metab Syndr. 2020; 14(1):17-21. DOI: 10.1016/j.dsx.2019.11.013
Kim HR, Han MA. Association between Serum Liver Enzymes and Metabolic Syndrome in Korean Adults. Int J Environ Res Public Health. 2018; 15(8):E1658. DOI: 10.3390/ijerph15081658
Yildirim B, Ozugurlu F, Sahin S, Ozyurt H, Atis O, Akbas A, et al. Association between elevated aminotransferase levels and the metabolic syndrome in Northern Turkey. Ann Hepatol. 2010 [acceso: 16/09/2021]; 9(2):161-5. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20526009/
Villegas R, Xiang Y-B, Elasy T, Cai Q, Xu W, Li H, et al. Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men. Metab Syndr Relat Disord. 2011; 9(4):305-11. DOI: 10.1089/met.2011.0016
Jiang W, Liu C-H, Wu D, Wang Y-J, Tang H. Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan. Biosci Rep. 2021; 41(12):BSR20211769. DOI: 10.1042/BSR20211769
Lizarzaburu Robles JC. SÃndrome metabólico: concepto y aplicación práctica. An Fac med. 2014; 74(4):315. DOI: 10.15381/anales.v74i4.2705
Chen QC, Xiao J, Zhang PP, Chen LL, Chen XX, Wang SM. Longitudinal Changes in Liver Aminotransferases Predict Metabolic Syndrome in Chinese Patients with Nonviral Hepatitis. Biomed Environ Sci. 2016; 29(4):254-66. DOI: 10.3967/bes2016.033
Zhang L, Ma X, Jiang Z, Zhang K, Zhang M, Li Y, et al. Liver enzymes and metabolic syndrome: a large-scale case-control study. Oncotarget. 2015; 6(29):26782-8. DOI: 10.18632/oncotarget.5792
Chen S, Guo X, Yu S, Zhou Y, Li Z, Sun Y. Metabolic Syndrome and Serum Liver Enzymes in the General Chinese Population. Int J Environ Res Public Health. 2016; 13(2):223. DOI: 10.3390/ijerph13020223
Liu C-F, Zhou W-N, Lu Z, Wang X-T, Qiu Z-H. The associations between liver enzymes and the risk of metabolic syndrome in the elderly. Exp Gerontol. 2018; 106:132-6. DOI: 10.1016/j.exger.2018.02.026
Perera S, Lohsoonthorn V, Jiamjarasrangsi W, Lertmaharit S, Williams MA. Association Between Elevated Liver Enzymes and Metabolic Syndrome Among Thai Adults. Diabetes Metab Syndr. 2008; 2(3):171-8. DOI: 10.1016/j.dsx.2008.04.012
Aliabadi PK, Sohrab M, Hessami A, Afshari M, Kashi Z, Kheradmand M, et al. Association between liver enzymes and metabolic syndrome: results of the enrollment phase of Tabari cohort. Ir J Med Sci. 2022;191(3):1201-08. DOI: 10.1007/s11845-021-02694-0
Ou Y-L, Lai Y-R, Jiang C-N, Zhang J, Ding Z. Diagnostic performance of individual characteristics and anthropometric measurements in detecting elevated serum alanine aminotransferase among children and adolescents. BMC Pediatr. 2020; 20:131. DOI: 10.1186/s12887-020-02033-9
Ding Z, Zhang J, Deng C-Y, You Y-B, Zhou H. Association of body mass index with serum alanine aminotransferase in Chinese adolescents: a school-based cross-sectional study. Gastroenterol Rep (Oxf). 2020; 8(2):119-24. DOI: 10.1093/gastro/goz039
Bekkelund SI, Jorde R. Alanine Aminotransferase and Body Composition in Obese Men and Women. Dis Markers. 2019; 2019:1695874. DOI: 10.1155/2019/1695874
Enlaces refback
- No hay ningún enlace refback.
URL de la licencia: https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es
La revista es de acceso abierto y gratuito.